

6th June, 2018

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: Notification

Dear Sir / Madam,

We are pleased to announce that the USFDA inspected the manufacturing facility of our wholly-owned subsidiary, Alidac Pharmaceuticals Ltd., located at SEZ, Ahmedabad from 28th May to 5th June, 2018. At the end of the inspection, no observation (483) is issued. The site manufactures oncology injectables for the regulated markets.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above